All articles tagged with #7 oh
Kratom and its concentrated derivative 7-OH are sparking a public health crisis across the U.S. Sold widely in gas stations and smoke shops without age restrictions, these substances are linked to overdoses, dependency, and neonatal withdrawal. While federal agencies flag them as dangerous, legislative responses vary by state, with some jurisdictions banning sales and others still debating regulations.
New York addiction specialists report a concerning trend of pregnant patients using kratom and newborns experiencing withdrawal. Dr. Angad Madan of St. Peter’s Addiction Recovery Center in Albany highlights that 7-OH, a concentrated kratom alkaloid, acts as a full opioid agonist with potency 13 times that of morphine. While Albany County recently banned the substance via emergency order, a statewide ban on 7-OH passed the state legislature but awaits Governor Hochul’s signature. Local law enforcement in Michigan and Memphis also warn that these products, often sold as supplements in gas stations, lack age restrictions and pose severe addiction risks.
A case study describes a 43-year-old man who developed opioid-like withdrawal after stopping high-dose 7-OH kratom products, a potent semi-synthetic derivative often marketed as kratom. Tests ruled out other causes, and doctors treated him with buprenorphine/naloxone and supportive care. The report underscores the potency difference between 7-OH and traditional kratom, rising poisoning reports, and the DEA’s tentative scheduling moves, while calling for clearer distinctions between leaf kratom and concentrated 7-OH products and better clinician guidance.
The DEA plans to temporarily place 7-OH, an opioid-like component of kratom, in Schedule I for two years (potentially extending to a third) for products above a certain threshold. Supporters say the move protects public health by curbing dependence and abuse, while critics question the science and warn it could hurt consumers who rely on kratom; the policy is framed as a win for the mainstream kratom industry amid political and lobbying dynamics.
New York doctors warn that kratom, especially the potent 7-OH variant, is the leading new substance addiction seen at SPARC, with withdrawal and opioid-like effects; marketed as a natural remedy but unregulated federally and linked to overdoses. State action is tightening controls, including a 21+ purchase age, as treatment centers warn of easy access and rising cases.
Laboratory analysis of a gas-station kratom pill revealed a potent, unlisted dose of 7-OH, an opioid-like chemical marketed as kratom and sold in gummies, drinks and even ice cream. The FDA says 7-OH could be the next wave of the opioid epidemic; CDC data link kratom to rising hospitalizations and deaths, especially when mixed with alcohol or other drugs. Because many products don’t disclose 7-OH on labels, consumers may not know what they’re taking. While some advocates push bans on 7-OH, others call for tighter labeling and professional guidance rather than outright prohibition.
NBA forward Brandon Clarke’s Arkansas arrest over kratom capsules—he told deputies, 'it's just kratom'—highlights a fiercely debated, poorly regulated plant that critics say can be addictive and dangerous. With Tennessee and other states weighing bans, the FDA warns of serious risks, while Arkansas already criminalized kratom; Clarke later died in California, with toxicology results pending and officials not confirming kratom as a factor. The case underscores ongoing questions about kratom’s medical value, safety, and the integrity of industry practices and sponsorships in sports.
Florida has become the first state to ban the sale of 7-hydroxymitragynine (7-OH), a potent kratom byproduct that acts like an opioid, classifying it as a Schedule I controlled substance following FDA recommendations, aiming to curb its use and potential health risks.
The FDA is targeting 7-hydroxymitragynine (7-OH), a potent, morphine-like compound found in kratom, which has gained popularity for its pain-relieving and mood-enhancing effects. While some advocate for its benefits, concerns about its high potency, potential for addiction, and unregulated production have led to calls for stricter regulation to ensure safety. Kratom's legal status varies across states, and the compound's effects are not fully understood, raising public health concerns.
The FDA has recommended classifying the synthetic compound 7-hydroxymitragynine (7-OH), found in unregulated products sold at gas stations and online, as a Schedule I illicit substance due to its potent opioid-like effects and associated health risks, prompting a review by the DEA.
The FDA is recommending scheduling 7-hydroxymitragynine (7-OH), a potent opioid byproduct of kratom, under the Controlled Substances Act to prevent abuse and protect public health, especially among youth, amid concerns over its increasing availability and potential for addiction.
The FDA is recommending regulatory action to control 7-hydroxymitragynine (7-OH), a potent opioid byproduct of the kratom plant, due to its abuse potential and presence in unregulated products, especially those appealing to youth. The agency emphasizes the risks and is working to prevent a new wave of opioid addiction by alerting healthcare professionals and consumers, and collaborating with the DEA for scheduling.
The FDA and health officials are planning to announce measures to crack down on synthetic products containing 7-OH, a potent opioid-like substance derived from kratom, which is increasingly found in various consumer products and raises safety concerns.